Adaptin Bio
Biotechnology company developing a platform to enhance delivery of immunotherapeutics to the brain and other target tissues. The company advances a bispecific antibody approach combined with specifically manipulated T cells to increase transport across the blood–brain barrier, with a lead program targeting EGFRvIII-positive glioblastoma and active preclinical and IND-stage work.
Industries
Nr. of Employees
small (1-50)
Adaptin Bio
3540 Toringdon Way, Suite 200, Charlotte, NC 28277
Products
APTN-101
An investigational brain-targeted bispecific therapeutic that binds a glioma-associated antigen (EGFRvIII) and CD3 to redirect T cells to tumor cells; designed to enhance brain distribution via immune-cell–mediated transport.
APTN-101
An investigational brain-targeted bispecific therapeutic that binds a glioma-associated antigen (EGFRvIII) and CD3 to redirect T cells to tumor cells; designed to enhance brain distribution via immune-cell–mediated transport.
Services
Design and execution of orthotopic animal efficacy studies, biodistribution assessments, and preclinical safety experiments to support IND-enabling decisions.
Preparation and submission of regulatory documentation and coordination with regulatory authorities to enable first-in-human studies.
Development of high-resolution targeted mass spectrometry assays for quantification of therapeutic proteins in plasma and whole blood.
Design and execution of orthotopic animal efficacy studies, biodistribution assessments, and preclinical safety experiments to support IND-enabling decisions.
Preparation and submission of regulatory documentation and coordination with regulatory authorities to enable first-in-human studies.
Development of high-resolution targeted mass spectrometry assays for quantification of therapeutic proteins in plasma and whole blood.
Expertise Areas
- Bispecific antibody development
- T cell redirection and immunoengineering
- Blood–brain barrier delivery strategies
- Preclinical brain tumor models and translational research
Key Technologies
- Bispecific T cell engagers (tumor antigen:CD3)
- T cell manipulation (in vivo and ex vivo)
- Blood–brain barrier transport via immune-cell hitchhiking
- Orthotopic intracerebral animal models
News & Updates
Press release announcing FDA clearance of an IND application for APTN-101, enabling initiation of a first-in-human Phase 1 clinical trial in glioblastoma.
Press release describing completion of a reverse merger transaction, private placement financing totaling approximately $7.7 million, and intent to trade on the OTC Markets to support clinical development activities.
Regulatory milestone enabling initiation of Phase 1 first-in-human clinical trial evaluating a brain-targeted bispecific therapeutic in glioblastoma.
Transaction and financing that provided approximately $7.7 million in gross proceeds to support clinical development and corporate activities.
Press release announcing FDA clearance of an IND application for APTN-101, enabling initiation of a first-in-human Phase 1 clinical trial in glioblastoma.
Press release describing completion of a reverse merger transaction, private placement financing totaling approximately $7.7 million, and intent to trade on the OTC Markets to support clinical development activities.
Regulatory milestone enabling initiation of Phase 1 first-in-human clinical trial evaluating a brain-targeted bispecific therapeutic in glioblastoma.
Transaction and financing that provided approximately $7.7 million in gross proceeds to support clinical development and corporate activities.